3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Revolve Group disclosed in an 8-K that unauthorized access to certain of its systems may have exposed names, contact details, payment card numbers and expiration dates for customers who saved payment information on its e-commerce platform. The company says the activity was remediated, there was no operational disruption, and it does not believe the incident will have a material impact on its business.
Unauthorized actor may have obtained, through automated means, customer names, contact information, payment card numbers and card expiration dates for customers who saved payment information.
Incident caused no operational disruption or interruption of service to customers, per the filing.
Company notified federal law enforcement and engaged external cybersecurity experts; it believes the incident will not have a material impact on its business.
Filing is dated October 29, 2026 and was signed by CFO Jesse Timmermans.
Armlogi Holding Corp. received a letter from Nasdaq on October 29, 2026, confirming it has regained compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market. Nasdaq closed the matter after the stock closed at or above $1.00 for 10 consecutive business days, from October 15 to October 28, 2026.
Nasdaq letter dated October 29, 2026 confirmed compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)
Closing bid price was at $1.00 or greater for 10 consecutive business days, October 15 to October 28, 2026
Nasdaq closed the matter, so the non-compliance issue is resolved
On October 23, 2026, Verisk issued a statement after the Delaware Supreme Court affirmed the Delaware Chancery Court judgment relating to its AccuLynx (ExactLogix) acquisition. Verisk said it will proceed in accordance with the order, but the filing states the transaction remains subject to customary closing conditions and FTC review and that there is no guarantee it will be completed.
October 23, 2026: Verisk issued a press release responding to the Delaware Supreme Court order on the ExactLogix (AccuLynx) merger.
The Delaware Supreme Court order affirmed the judgment of the Delaware Chancery Court.
Verisk says the transaction remains subject to customary closing conditions and FTC review, and that there is no guarantee it will be completed.
Propanc Biopharma received a Nasdaq notice on October 23, 2026, saying its common stock no longer meets the $1.00 minimum bid price. Because the company had a reverse stock split in the prior year, it is not eligible for a standard compliance period, and Nasdaq says the stock will be delisted on November 2, 2026 unless the company appeals by October 30, 2026. The company intends to appeal, which would stay the delisting, and says it has since cured the deficiency; a delisting would hurt the stock's liquidity and its ability to raise capital.
Nasdaq notice dated October 23, 2026 cites non-compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2)
Stock was below $1.00 based on closing bid prices for the 30 consecutive business days before October 21, 2026
Scheduled delisting from The Nasdaq Capital Market on November 2, 2026, unless an appeal to a hearings panel is requested by October 30, 2026
Company intends to request the appeal, which would keep the stock listed until the Panel decides
Greenland Energy Company received a Nasdaq letter after director Roderick McIllree resigned on October 20, 2026, leaving it out of compliance with Nasdaq's majority independent director and audit committee requirements. The company says it appointed Melanie Furlan to the audit committee on October 27, 2026, curing the audit committee deficiency, and its common stock and warrants remain listed. The company must still regain majority independence within the cure period, which runs to the earlier of its next annual meeting or October 20, 2027, with an April 19, 2027 deadline if that meeting occurs before then.
Director Roderick McIllree resigned October 20, 2026, triggering the non-compliance.
Nasdaq letter dated October 28, 2026 set a cure period ending the earlier of the next annual meeting or October 20, 2027.
Audit committee deficiency cured October 27, 2026 by appointing Melanie Furlan; committee now includes Furlan, Scott Wollney and Carol Craig.
Common stock (GLND) and public warrants (GLNDW) continue trading on the Nasdaq Global Market.
Nasdaq's Hearings Panel granted CID HoldCo (Nasdaq: DAIC) continued listing, notified the company on October 28, 2026, but requires an application to transfer the listing to The Nasdaq Capital Market by November 2, 2026. The filing also reports that the Envoy Technologies acquisition closed on October 9, 2026, and that BladeRanger's designee, Avi Cohen, joined the board on October 23, 2026, so shareholders face a conditional listing outcome alongside a completed acquisition.
Nasdaq Hearings Panel granted continued listing, subject to submitting a transfer application to The Nasdaq Capital Market on or before November 2, 2026
Company closed the acquisition of 100% of Envoy Technologies' capital stock on October 9, 2026, paid in common stock and newly authorized Series C Convertible Non-Redeemable Preferred Stock
Avi Cohen appointed to the board on October 23, 2026, to Class I, serving until the 2029 Annual Meeting; filing states he is independent
Company filed its delinquent Form 10-Q for the quarter ended June 30, 2026, and issued a press release on October 29, 2026
Enanta Pharmaceuticals said the Unified Patent Court of the European Union ruled on October 29, 2026 that its European Patent No. EP 4 051 265 is invalid and that its infringement action against Pfizer was unfounded. The ruling ends Enanta's infringement claim over Pfizer's Paxlovid sales in the 18 participating EU member states, which the filing does not quantify.
Court decision released October 29, 2026, following a hearing held September 29, 2026
UPC concluded the '265 Patent is invalid, responding to Pfizer's counterclaim for revocation
Court also found the infringement action unfounded in light of the validity decision
Filing does not state any financial impact, damages, or next steps
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.